Top Stories – [your]NEWS
yournews.com
German-Hungarian research finds spike protein clumps trapped in cardiac tissue; Kennedy’s funding shift and Massie’s demands intensify vaccine policy clash.
By yourNEWS Media Newsroom
A newly accepted Frontiers in Immunology study led by German and Hungarian scientists is raising alarm over mRNA COVID-19 vaccines, reporting that “numerous off-target products” created during translation of the encoded spike protein become trapped inside heart cells, potentially contributing to both acute and long-term side effects.
The peer-reviewed paper, reported by Just the News, and slated for final publication soon, found that Pfizer and Moderna’s mRNA vaccines triggered the production of spike protein monomers that were inconsistently cleaved into S2 subunits, depending on cell type and vaccine. Within hours, researchers observed “large, sticky aggregates” forming in unique patterns inside cells, including cardiac cells, where they slowed growth, induced oxidative stress, and triggered inflammation. According to TrialSiteNews, these “sticky spike clumps” remained trapped in cells, with only the secreted S1 subunit detected in supernatant samples, raising new questions about post-vaccination spike protein behavior.
The findings arrive amid a political and scientific battle over mRNA technology. Health and Human Services Secretary Robert F. Kennedy Jr. recently redirected nearly $500 million in federal funding away from mRNA development toward “safer, broader vaccine platforms” capable of maintaining effectiveness despite viral mutation. His move drew criticism from the public health establishment, mainstream media, and even some old-guard conservatives.
National Review editors defended COVID-19 vaccines for allegedly reducing hospitalization and death by 70%, citing Biden administration CDC data, even while noting the virus became “less severe over time.” The magazine’s intern called them “the most phenomenal medical breakthrough of the 21st century,” despite admissions from then-CDC Director Rochelle Walensky that they failed to stop infection or transmission just a month after emergency authorization.
Other peer-reviewed findings are compounding scrutiny. Japanese researchers, writing in Cancers, reported that as few as two primary doses and a booster correlated with poorer survival in pancreatic cancer patients. Preprint research by former Trump administration FDA and CDC advisers found higher-than-expected pregnancy losses after early mRNA vaccination in Israeli medical data.
Critics say Kennedy’s funding shift is overdue. Former EcoHealth Alliance Vice President Andrew Huff called it “the first real policy course correction in a vaccine ecosystem that had drifted from science into speculative biotech fantasy,” outlining alternatives such as mucosal vaccines that could block infection at entry points and generate broad, lasting immunity.
Supporters of mRNA vaccines point to a Danish Journal of the American Medical Association study claiming they are “incredibly safe” in elderly recipients of three prior doses, though critics noted the absence of an unvaccinated control group, the exclusion of severe adverse events after 28 days, and the study’s own myocarditis signal.
Meanwhile, Kennedy’s FDA has approved Moderna’s newest mRNA shot for higher-risk individuals, reauthorized an older version for at-risk children, and announced it will not approve annual boosters for healthy adults under 65 without trials. Kennedy also approved removal of mercury-based thimerosal from flu vaccines, still present in some multi-dose vials decades after its phaseout from childhood shots.
For Kentucky GOP Rep. Thomas Massie, such measures fall short. He is calling for the FDA to “immediately revoke licensure of the mRNA COVID shots” over what he deems a “shoddy approval process and known side effects.”
The Frontiers in Immunology findings, alongside growing peer-reviewed literature on adverse outcomes, are likely to intensify the debate between federal regulators, vaccine defenders, and skeptics pressing for an end to mRNA authorization.
FDA-Approved mRNA Vaccines in the U.S.
